Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.71 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.69 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260500 | 0.83 | KMT2A (1.00) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL6263371 | 0.81 | KMT2A (0.77) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL6264004 | 0.80 | KMT2A (0.76) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL12635981 | 0.79 | KMT2A (1.00) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL6259571 | 0.79 | KMT2A (0.74) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL6263607 | 0.79 | RXFP1 (0.75) | KMT2AMEN1CTDSP1CASP3KDM4E | |
| SCHEMBL12635988 | 0.79 | KMT2A (1.00) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL6264128 | 0.78 | CASP3 (0.86) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL6260508 | 0.77 | KDM4E (0.68) | KMT2AMEN1CTDSP1POLBCASP3 | |
| SCHEMBL2914329 | 0.76 | TRPV1 (0.74) | KMT2AMEN1TRPV1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS | 2022-02-03 | — | — | US | disclosed |
| WO-2020117832-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | BLVRB, TFPI, ETFB | KMT2A 3788/4885MEN1 4178/4885CTDSP1 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.